Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States
JCO Global Oncology · 2024
DOI: 10.1200/go.24.00138 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Stephen V Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Anti–PD-1/PD(L)1-based combination therapy is the standard of care in first line (1L) for metastatic nonsquamous non–small cell lung cancer (mnsqNSCLC) without driver alterations. This study aimed to evaluate real-world clinical outcomes in this population. METHODS Eligible physicians in the United States, Europe, and Japan abstracted information from medical charts of eligible adult patients with mnsqNSCLC (without EGFR/ ALK, no known ROS1 alterations) who initiated 1L anti–PD(L)1-based combination therapy for mnsqNSCLC between 2017 and 2021. Kaplan-Meier analyses were used to assess overall survival (OS), time-to-treatment discontinuation (TTD), and real-world progression-free survival (rwPFS) after 1L initiation. RESULTS Overall, 142 physicians contributed deidentified data from 430 patients' medical charts. The distribution of PD-L1 expression levels was 31.2% with tumor proportion score (TPS)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
- Eisai Inc, Nutley, NJ.
- Analysis Group, Inc, Montréal, Canada.
- Merck & Co, Inc, Rahway, NJ.
- Gustave Roussy Institute, Paris Saclay University, Paris, France.
- Winship Cancer Institute, Emory University, Atlanta, GA.
ORCID-Profile: Stephen V Liu, Dominick Latremouille-Viau, Carmine Rossi, Pragya Rai, Ticiana A Leal
Zitieren
APA
Liu, S. V., Dasgupta, A., Latremouille-Viau, D., Rossi, C., Rai, P., Barlesi, F., & Leal, T. A. (2024). Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States. JCO Global Oncology. https://doi.org/10.1200/go.24.00138
Vancouver
Liu SV, Dasgupta A, Latremouille-Viau D, Rossi C, Rai P, Barlesi F, et al. Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States. JCO Global Oncology. 2024. doi:10.1200/go.24.00138
BibTeX
@article{Liu2024,
author = {Liu, Stephen V and Dasgupta, Anandaroop and Latremouille-Viau, Dominick and Rossi, Carmine and Rai, Pragya and Barlesi, Fabrice and Leal, Ticiana A},
title = {Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States},
journal = {JCO Global Oncology},
year = {2024},
doi = {10.1200/go.24.00138}
}
EUVIMED